Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference
Sol-Gel Technologies, a clinical-stage dermatology firm, will present a company overview at two upcoming virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sol-Gel Technologies, a clinical-stage dermatology firm, will present a company overview at two upcoming virtual investor conferences. The first is the Jefferies Healthcare Conference, scheduled for June 1, 2021, where CEO Dr. Alon Seri-Levy will speak at 8:30 am EDT. The second is the Raymond James Human Health Innovation Conference on June 22, 2021, at 10:00 am EDT. The company focuses on developing topical treatments for skin diseases, with NDA submissions for two products pending FDA review. Recordings of the presentations will be available on their website.
Details
News Market Reaction – SLGL
The recorded move for SLGL in the trading session of this news was +2.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences:
| Jefferies Healthcare Conference (June 1 – 4, 2021) | |
| Speaker: | Dr. Alon Seri-Levy, Chief Executive Officer |
| Date: | Tuesday, June 1, 2021 |
| Time: | 8:30 – 8:55 am EDT |
| Raymond James Human Health Innovation Conference | |
| (June 21 – 23, 2021) | |
| Speaker: | Dr. Alon Seri-Levy, Chief Executive Officer |
| Date: | Tuesday, June 22, 2021 |
| Time: | 10:00 – 10:30 am EDT |
A recording of the webcast of each presentation will be available in the Investors/Events & Presentations section of the Company’s website at www.sol-gel.com.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for the development of TWYNEO®, under investigation for the treatment of acne vulgaris with an NDA filed with the FDA and a PDUFA goal date set for August 1, 2021; and EPSOLAY®, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date set for April 26, 2021. Action on the NDA for EPSOLAY has not yet been taken due to the inability of the FDA to conduct a pre-approval inspection of the production site of EPSOLAY as a result of COVID-19 travel restrictions. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, under investigation for the treatment of palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.
For further information, please contact:
| Sol-Gel Technologies |
| Gilad Mamlok Chief Financial Officer +972-8-9313433 |
| Investor relations Irina Koffler LifeSci Advisors +1-917-734-7387 ikoffler@lifesciadvisors.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.